Small Molecule vs JAK Inhibitor — Immunology Deal Terms Comparison
Market Analysis
In immunology, Small Molecule and JAK Inhibitor represent two of the most actively transacted modalities. At Phase 2, Small Molecule deals carry a median total deal value of $2.4B with $466M upfront, compared to $2.7B total value and $513M upfront for JAK Inhibitor. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Small Molecule development milestones average $393M versus $432M for JAK Inhibitor. Commercial milestones are $884M for Small Molecule and $973M for JAK Inhibitor. Royalty rates range from 13.1%-21.9% for Small Molecule and 13.5%-22.5% for JAK Inhibitor.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Small Molecule and JAK Inhibitor deal terms compare in immunology?
Which modality commands higher royalty rates: Small Molecule or JAK Inhibitor?
How do milestone structures differ between Small Molecule and JAK Inhibitor?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.